GLOBAL BLOOD THERAPEUTICS IN's ticker is GBT and the CUSIP is 37890U108. A total of 247 filers reported holding GLOBAL BLOOD THERAPEUTICS IN in Q3 2022. The put-call ratio across all filers is 0.56 and the average weighting 0.6%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2022 | $158,145,000 | +64.2% | 2,322,247 | -23.0% | 4.59% | +52.1% |
Q2 2022 | $96,331,000 | -28.6% | 3,015,054 | -22.5% | 3.02% | +11.7% |
Q1 2022 | $134,836,000 | -33.2% | 3,892,493 | -43.6% | 2.70% | +73.4% |
Q4 2021 | $201,958,000 | +79.8% | 6,899,830 | +56.6% | 1.56% | -4.5% |
Q3 2021 | $112,300,000 | -61.4% | 4,407,399 | -46.9% | 1.63% | -13.7% |
Q2 2021 | $290,854,000 | +41.1% | 8,305,378 | +64.2% | 1.89% | -27.5% |
Q1 2021 | $206,139,000 | -16.1% | 5,058,642 | -10.9% | 2.61% | -1.2% |
Q4 2020 | $245,771,000 | -23.2% | 5,674,711 | -2.2% | 2.64% | -43.5% |
Q3 2020 | $319,867,000 | -13.3% | 5,800,996 | -0.7% | 4.67% | -21.9% |
Q2 2020 | $368,811,000 | +19.0% | 5,842,100 | -3.7% | 5.98% | -26.0% |
Q1 2020 | $309,897,000 | -33.5% | 6,065,726 | +3.4% | 8.07% | -12.9% |
Q4 2019 | $466,266,000 | +63.6% | 5,865,726 | -0.2% | 9.26% | +20.6% |
Q3 2019 | $285,090,000 | -6.2% | 5,875,726 | +1.7% | 7.68% | +10.2% |
Q2 2019 | $303,803,000 | +3.9% | 5,775,726 | +4.5% | 6.97% | -15.5% |
Q1 2019 | $292,476,000 | +31.3% | 5,525,726 | +1.8% | 8.25% | -2.6% |
Q4 2018 | $222,726,000 | +13.8% | 5,425,726 | +5.4% | 8.48% | +62.0% |
Q3 2018 | $195,658,000 | -10.4% | 5,148,910 | +6.6% | 5.23% | -8.6% |
Q2 2018 | $218,266,000 | -9.4% | 4,828,910 | -3.2% | 5.72% | -15.2% |
Q1 2018 | $240,971,000 | +25.3% | 4,989,066 | +2.0% | 6.75% | +5.8% |
Q4 2017 | $192,384,000 | -27.3% | 4,889,066 | -42.7% | 6.38% | +26.1% |
Q3 2017 | $264,798,000 | +146.1% | 8,528,132 | +116.8% | 5.06% | -6.6% |
Q2 2017 | $107,592,000 | -24.3% | 3,933,927 | +1.9% | 5.41% | -33.2% |
Q1 2017 | $142,203,000 | +214.5% | 3,858,978 | +23.3% | 8.10% | +152.0% |
Q4 2016 | $45,213,000 | -16.0% | 3,128,978 | +34.1% | 3.22% | -7.4% |
Q3 2016 | $53,802,000 | +46.9% | 2,334,168 | +5.7% | 3.47% | +36.8% |
Q2 2016 | $36,625,000 | +78.0% | 2,207,668 | +70.2% | 2.54% | +40.7% |
Q1 2016 | $20,577,000 | -46.4% | 1,297,468 | +9.3% | 1.80% | -36.4% |
Q4 2015 | $38,363,000 | -50.6% | 1,186,630 | -35.6% | 2.84% | -8.6% |
Q3 2015 | $77,726,000 | – | 1,843,600 | – | 3.10% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Alerce Investment Management, L.P. | 356,270 | $24,262,000 | 23.36% |
Twin Securities, Inc. | 376,669 | $25,651,000 | 11.94% |
Paradigm Biocapital Advisors LP | 1,175,879 | $80,077,000 | 10.68% |
Chicago Capital Management, LLC | 246,246 | $16,769,000 | 9.12% |
HARVEST MANAGEMENT LLC | 141,500 | $9,636,000 | 7.78% |
Fernwood Investment Management, LLC | 174,724 | $11,899,000 | 5.02% |
ArchPoint Investors | 168,725 | $11,490,000 | 4.69% |
HAVENS ADVISORS LLC | 46,000 | $3,133,000 | 4.69% |
Perceptive Advisors | 2,322,247 | $158,145,000 | 4.59% |
Crabel Capital Management, LLC | 112,680 | $7,674,000 | 4.48% |